Landing page header.png

iNANOD

 Nanotechnology based Cancer Drug Development

ABOUT iNANOD

iNANOD, based in Oslo Cancer Cluster Incubator, is developing new technology in cancer treatment that relies on nano-vehicles to pack and cargo the payload drug in a controlled way.

 

This technology is expected to result in enhanced drug penetration and efficacy by delivering the right drug in the right tissues in the right amount and within the right time duration.

THE PROBLEM

As per the World Health Organization, 9.6 million people died from cancer in 2018 (1 out of 6 deaths worldwide). Today, cancer patients suffer from a high rate of undesired side effects while under chemotherapy. Most cancer drugs are not site-specific.

 

Max 0.2% of small molecule cancer drugs reach cancer cells, while the rest spread over the body and impart unintended adverse effects on healthy cells.

THE SOLUTION

NANOparticle2_edited.jpg

An innovative platform technology for cancer drug-delivery with the potential to disrupt the cancer drugs market.

iNANOD’s technology combines individually proven technologies to improve drug delivery and reduce side effects.

We detected the need to incorporate cutting-edge technology in modern cancer treatments and aims to add value by introducing accelerated uptake involving a time parameter.

Our objective is to develop a platform technology for shorter chemotherapy with fewer side effects.

OUR PROPOSAL

THE PEOPLE

BOARD MEMBERS

Portrait_004_Åge_Master.jpg

Åge Nærdal

Trained as a Pharmacist having more than 35 years of experience in leadership from pharmaceutical industry.

Chairman

Nalinava3.jpg

Nalinava Sengupta

Board Member & CEO

After 15 years of academic research in chemistry, turned entrepreneur for a mission.

Hilde2.jpg

Hilde Nilsen

Board Member

Professor in Department of Clinical Molecular Biology,  Head (Epigenetics), Akershus University Hospital.

Jørn.jpg

Jørn Lein-Mathisen

Board Member

Business angel. Business development and entrepreneurial experiences internationally over 28 years.

Per.jpg

Per Foss

Bio-organic chemistry doctorate having hugely diverse professional expertise in the industry.

Board Member

MILESTONES ACHIEVED

  • The technology has been reviewed scientifically by key opinion leaders in drug development in Norway.

  • Recent publications in scientific journals supporting iNANOD's underlying technology.

  • iNANOD filed a prophetic patent in the UK in April 2021

  • iNANOD established a strong board and advisory team bringing together experts with scientific and commercial expertise in drug development.

  • iNANOD also established collaborations with various industry partners including SINTEF Industry , Nordic Biosite, and Innoplexus.

  • Through these collaborations and also third-party CROs, iNANOD plans to run a very lean organization and cost structure.

FUNDRAISING ROUND AND PURPOSE

 

iNANOD is raising NOK 5 million at a pre-money valuation of NOK 25 million. 

The Company previously raised ca. NOK 1.8 million in 2018 and 2019 in the previous rounds led by business angels.

As the next step in the drug development process, iNANOD will focus on reaching Proof-of-Principle (PoP) in the next two years.  This requires CMC stage work (liposome optimization, synthesis and characterization), followed by in vivo and in vitro testing of the lead candidates and animal models of testing to generate pre-clinical data.

 

The funds raised in this round will primarily be deployed to start the CMC stage R&D work (liposome optimization, synthesis and characterization against 51 different cancer cell lines) in collaboration with SINTEF.

Drug development process.png

If iNANOD is successful in reaching PoP, the Company will engage in further fundraising to fund phase I and phase II clinical trials, with a view to entering into a licensing deal with Big Pharma after phase IIb.  A typical licensing deal includes an upfront payment, milestone payments, and royalty fees.

TAKE THE NEXT STEP

If you’re interested in investing in iNANOD, please enter your contact information below. We’ll get in touch with you.

Thank you for your interest in iNANOD! We will be in touch soon.